Welcome to our dedicated page for ISPIRE TECHNOLOGY SEC filings (Ticker: ISPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ispire Technology鈥檚 dual exposure to FDA-regulated e-cigarettes and rapidly changing cannabis laws packs its SEC reports with regulatory nuance, ODM contract details and patent debates that easily exceed 250 pages. Finding where the 10-K explains PMTA status or which Form 4 shows an executive selling shares after a new vape launch can feel impossible.
Our platform solves that. Stock Titan鈥檚 AI reads every Ispire Technology quarterly earnings report 10-Q filing, scans 8-K material events, and flags insider trading Form 4 transactions the moment they hit EDGAR. Interactive summaries explain section-by-section what each disclosure means鈥攚hether you鈥檙e tracking supply-chain risks in Shenzhen or assessing cannabis segment margins. Need a quick brief? Click the 鈥淚spire Technology SEC filings explained simply鈥� card; you鈥檒l see revenue by product line, fresh litigation updates and executive compensation highlights drawn straight from the proxy. AG真人官方-time alerts ensure you never miss an 鈥淚spire Technology Form 4 insider transactions real-time鈥� update.
Investors use these insights to: monitor regulatory milestones signaled in 8-Ks, compare nicotine vs. cannabis growth across quarters, and study 鈥淚spire Technology executive stock transactions Form 4鈥� before earnings. Every document type鈥�10-K, 10-Q, 8-K, DEF 14A鈥攕its one click away, already distilled by AI so you can focus on decisions, not deciphering. Understanding Ispire Technology SEC documents with AI means hours saved and a clearer view of how patents, manufacturing partnerships and global compliance shape future cash flows.
Form 4 highlights for Rhythm Pharmaceuticals, Inc. (RYTM)
- Reporting insider: Chief Financial Officer Hunter C. Smith
- Transaction date: 07/09/2025 (filed 07/11/2025)
- Option exercise: 42,120 stock options exercised at an exercise price of $6.88.
- Share sales: The same 42,120 shares were immediately disposed of in three open-market sales:
- 17,113 shares at a weighted average price of $75.3842
- 1,607 shares at a weighted average price of $76.1707
- 23,400 shares at a price of $84.50
- Proceeds (approx.): About $3.2 million based on the weighted average sale prices disclosed.
- Remaining holdings: 116,915 shares of common stock held directly after the transactions, plus 28,088 fully vested options that remain outstanding.
- 10b5-1 plan: Sales were executed under a Rule 10b5-1 trading plan adopted on 02/28/2025.
The filing indicates a net reduction of roughly 26% in the CFO鈥檚 direct common-stock position (from 159,035 to 116,915 shares). No information about company fundamentals or operational performance is included; the document is limited to insider trading activity.
On 11 July 2025, I-MAB (Nasdaq: IMAB) submitted a Form 6-K to notify investors that it has amended its 15 May 2025 prospectus covering the offer and sale of up to US$21 million in American Depositary Shares (ADSs). Each block of ten ADSs represents twenty-three ordinary shares with a par value of US$0.0001. The prospectus is part of the company鈥檚 shelf Registration Statement on Form F-3 (File No. 333-286954).
The filing attaches a Cayman Islands legal opinion from Harney Westwood & Riegels (Exhibit 5.1) together with the corresponding consent (Exhibit 23.1), confirming the validity of the ADSs and underlying ordinary shares. The 6-K states that the information and exhibits are incorporated by reference into the existing Form F-3 and several Form S-8 registration statements covering share-based compensation plans.
No operating or financial results are disclosed. The amendment maintains regulatory compliance and keeps the shelf registration effective, giving I-MAB flexibility to raise up to US$21 million when market conditions permit. While this improves liquidity options, it may also lead to equity dilution for current shareholders if the full amount is issued.
On 11 July 2025, I-MAB (Nasdaq: IMAB) submitted a Form 6-K to notify investors that it has amended its 15 May 2025 prospectus covering the offer and sale of up to US$21 million in American Depositary Shares (ADSs). Each block of ten ADSs represents twenty-three ordinary shares with a par value of US$0.0001. The prospectus is part of the company鈥檚 shelf Registration Statement on Form F-3 (File No. 333-286954).
The filing attaches a Cayman Islands legal opinion from Harney Westwood & Riegels (Exhibit 5.1) together with the corresponding consent (Exhibit 23.1), confirming the validity of the ADSs and underlying ordinary shares. The 6-K states that the information and exhibits are incorporated by reference into the existing Form F-3 and several Form S-8 registration statements covering share-based compensation plans.
No operating or financial results are disclosed. The amendment maintains regulatory compliance and keeps the shelf registration effective, giving I-MAB flexibility to raise up to US$21 million when market conditions permit. While this improves liquidity options, it may also lead to equity dilution for current shareholders if the full amount is issued.
Ispire Technology (Nasdaq: ISPR) filed an 8-K detailing the results of its June 24, 2025 Annual Meeting.
- Directors elected: Tuanfang Liu, Jiangyan Zhu, Christopher R. Burch, Brent Cox and John Fargis were re-elected for one-year terms. Support ranged from 98.7% to 99.7% of votes cast, with 9.47 million broker non-votes.
- Auditor ratified: Marcum Asia LLP received 49,580,681 votes for (99.98%) and 7,657 against to serve for fiscal year ending June 30, 2025.
- Quorum achieved: 49.59 million shares (86.8% of the 57.14 million outstanding) were present in person or by proxy.
No additional proposals or material business changes were reported.
Initial Statement of Beneficial Ownership (Form 3) filed by Jay Yu, who serves as the Chief Financial Officer of Ispire Technology (NASDAQ: ISPR). The filing was submitted on June 28, 2025, following Yu's appointment which required disclosure as of May 13, 2025.
Key details:
- Yu currently holds no beneficial ownership of any securities in the company, either direct or indirect
- No derivative securities (options, warrants, convertible securities) are reported
- Filing includes a Power of Attorney (Exhibit 24.1)
- The document was signed by Jay Yu on June 20, 2025
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders to disclose their initial securities ownership positions within 10 days of becoming an insider.
FAQ
What is the current stock price of ISPIRE TECHNOLOGY (ISPR)?
What is the market cap of ISPIRE TECHNOLOGY (ISPR)?
What core products does Ispire Technology Inc. offer?
How does Ispire generate revenue?
What differentiates Ispire's technology in the vaping market?
Which global markets does Ispire serve?
How does Ispire ensure product safety and regulatory compliance?
What role do ODM partnerships play in Ispire's business model?
What is the significance of Ispire's patent portfolio?
How does Ispire address sustainability in its product offerings?
